Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.
The New England Journal of Medicine reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
The company can now move forward with a late-stage study of its lead pipeline candidate.
March S&P 500 futures (ESH23) are trending up +0.17% this morning after three major U.S. benchmark indices closed sharply lower on Thursday, with the technology-heavy Nasdaq dropping the most after stronger-than-expected...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors...
Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following...
AMF REGULATED INFORMATIONMontrouge, France, July 27, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (Article 223-16 of the...
Let's consider the risk-reward profile of these companies before jumping on the bandwagon.